Video

Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03

Author(s):

Sponsored Content

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
illustration of gynecologic cancer
Picture of Dr. Thomas Jankowski
Picture of Dr. Jacob Sands
Related Content
Dr. Paul Gellhaus says PSA testing and modern biopsy methods ease fears and reassure patients, making early prostate cancer detection safe and valuable.
September 12th 2025

Early Prostate Cancer Detection: Why PSA Screening Matters

Dr. Paul Gellhaus
Kristen Dahlgren of the Cancer Vaccine Coalition spoke with CURE about why she remains hopeful for the future or cancer vaccines.
September 12th 2025

Could Cancer Vaccines Become a Reality Within the Next Decade?

Kristen Dahlgren
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
September 12th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
September 12th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
image of dr. Lillian Siu.
September 12th 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer
September 12th 2025

Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer

Ryan Scott